In preclinical studies, γδ CAR-T cells targeting CD19, CD123, and CD20 have shown potent anti-tumour activity in leukaemia and lymphoma models, with significant tumour burden reduction in vivo [364–366]​. This evidence concerns the gene CD19 and neoplasm.